human ibc cell line sum149  (BioIVT Inc)

Journal: Cancers

Article Title: Anti-Angiogenic Treatments Interact with Steroid Secretion in Inflammatory Breast Cancer Triple Negative Cell Lines

doi: 10.3390/cancers13153668

Figure Lengend Snippet: In vitro VEGF (0.62, 1.25, 2.5 uM), SU5416, bevacizumab and celecoxib (1.5, 3, 6 uM) effects on cell viability after 24 h, 48 h and 72 h post-treatment in IPC-366 and SUM149 cell lines measured by MTS assay. Cell viability increases after VEGF addition in both cell lines ( A , B ). Cell viability decreased after SU5416 treatment in IPC-366 cells and increased in SUM149-treated cells ( C , D ). Decreased cell viability in IPC-366- and SUM149 treated cells after bevacizumab ( E , F ) and celecoxib ( G , H ) addition. Data are shown as means ± SEM. * Significant differences between control and treated groups ( p < 0.05).

Article Snippet: The SUM149 triple-negative human IBC cell line was originally obtained from Asterand, Plc. (Detroit, MI, USA) and was grown in Ham’s F-12 medium (Invitrogen, 21765029) supplemented with 5% FBS (Sigma Aldrich, 12103C), 1 ug/mL hydrocortisone (Sigma Aldrich, H4001), 5 ug/mL insulin (Sigma Aldrich, I9278) and 1% penicillin-streptomycin solution (Sigma Aldrich, P0781).

Techniques: In Vitro, MTS Assay, Control

Journal: Cancers

Article Title: Anti-Angiogenic Treatments Interact with Steroid Secretion in Inflammatory Breast Cancer Triple Negative Cell Lines

doi: 10.3390/cancers13153668

Figure Lengend Snippet: Tube formation results. ( A ) Images ×10 of IPC-366 and SUM149 vascular-like structures (arrows) formed in control and treated groups treated with a final concentration of 1.5 uM for VEGF, SU5416, bevacizumab and celecoxib. Bar graph represents percentage of number of tubes formed at 6 h respect to control group. ( B ) Steroid precursor (P4, DHEA, A4); ( C ) sexual steroids (T, DHT, E2, E1SO4) and ( D ) angiogenic growth factors (VEGF-A, VEGF-C, VEGF-D, IL-8) in culture media of IPC-366 (black) and SUM149 (grey) after tube formation assay. * Denoted significant differences ( p < 0.05) between control and treated groups. Scale bar 200 µM.

Article Snippet: The SUM149 triple-negative human IBC cell line was originally obtained from Asterand, Plc. (Detroit, MI, USA) and was grown in Ham’s F-12 medium (Invitrogen, 21765029) supplemented with 5% FBS (Sigma Aldrich, 12103C), 1 ug/mL hydrocortisone (Sigma Aldrich, H4001), 5 ug/mL insulin (Sigma Aldrich, I9278) and 1% penicillin-streptomycin solution (Sigma Aldrich, P0781).

Techniques: Control, Concentration Assay, Tube Formation Assay

Journal: Cancers

Article Title: Anti-Angiogenic Treatments Interact with Steroid Secretion in Inflammatory Breast Cancer Triple Negative Cell Lines

doi: 10.3390/cancers13153668

Figure Lengend Snippet: In vivo effect of VEGF, SU5416, bevacizumab and celecoxib on tumour growth in xenotransplanted mice of ( A , C , E , G ) IPC-366 and ( B , D , F , H ) SUM149. Bar represents means ± SEM. * Significant differences between control and treatment groups ( p < 0.05).

Article Snippet: The SUM149 triple-negative human IBC cell line was originally obtained from Asterand, Plc. (Detroit, MI, USA) and was grown in Ham’s F-12 medium (Invitrogen, 21765029) supplemented with 5% FBS (Sigma Aldrich, 12103C), 1 ug/mL hydrocortisone (Sigma Aldrich, H4001), 5 ug/mL insulin (Sigma Aldrich, I9278) and 1% penicillin-streptomycin solution (Sigma Aldrich, P0781).

Techniques: In Vivo, Control

Journal: Cancers

Article Title: Anti-Angiogenic Treatments Interact with Steroid Secretion in Inflammatory Breast Cancer Triple Negative Cell Lines

doi: 10.3390/cancers13153668

Figure Lengend Snippet: Foci of pulmonary and hepatic metastasis in control and experimental groups of IPC-366 and SUM149.

Article Snippet: The SUM149 triple-negative human IBC cell line was originally obtained from Asterand, Plc. (Detroit, MI, USA) and was grown in Ham’s F-12 medium (Invitrogen, 21765029) supplemented with 5% FBS (Sigma Aldrich, 12103C), 1 ug/mL hydrocortisone (Sigma Aldrich, H4001), 5 ug/mL insulin (Sigma Aldrich, I9278) and 1% penicillin-streptomycin solution (Sigma Aldrich, P0781).

Techniques: Control

Journal: Cancers

Article Title: Anti-Angiogenic Treatments Interact with Steroid Secretion in Inflammatory Breast Cancer Triple Negative Cell Lines

doi: 10.3390/cancers13153668

Figure Lengend Snippet: Metastatic foci in lungs and liver after VEGF, SU5416, bevacizumab and celecoxib treatment in IPC-366 and SUM149 xenotransplanted mice. ( A ) SUM149 control mice lung with metastatic focus. ( B ) IPC-336 control mice liver with large metastic focus. ( C , D ). Foci of metastases in lung and liver after VEGF inoculation in IPC-366- (c) and SUM149- (d) xenotransplanted mice. ( F ) Multiple small foci of metastasis in the lung of SUM-149 mice treated with 5 mg/kg of SU5416. ( G , H ). Absence of metastatic foci after bevacizumab treatment in IPC-366 xenografted mice. ( I ) Small foci of metastasis after inoculation (0.5 mg/kg) of celecoxib.

Article Snippet: The SUM149 triple-negative human IBC cell line was originally obtained from Asterand, Plc. (Detroit, MI, USA) and was grown in Ham’s F-12 medium (Invitrogen, 21765029) supplemented with 5% FBS (Sigma Aldrich, 12103C), 1 ug/mL hydrocortisone (Sigma Aldrich, H4001), 5 ug/mL insulin (Sigma Aldrich, I9278) and 1% penicillin-streptomycin solution (Sigma Aldrich, P0781).

Techniques: Control

Journal: Cancers

Article Title: Anti-Angiogenic Treatments Interact with Steroid Secretion in Inflammatory Breast Cancer Triple Negative Cell Lines

doi: 10.3390/cancers13153668

Figure Lengend Snippet: In vivo tumour homogenate and serum sex steroid hormones, angiogenic growth factors and IL-8 concentrations in IPC-366- and SUM149 xenotransplanted mice after inoculation of the high dosage of VEGF (1 mg/kg), SU5416 (10 mg/kg), bevacizumab (10 mg/kg) and celecoxib treatment (5 mg/kg). Bar represents means ± SEM. * Significant differences between control and treatment groups ( p < 0.05). ( A ) Serum P4 levels were no altered but its intratumoral concentrations decreased after SU5416 and celecoxib. ( B ) Serum DHEA levels decreased after VEGF, SU5416 and celecoxib and no changes in its intratumoral concentrations were found after all treatments. ( C ) Serum and intratumoral A4 levels decreased after VEGF, bevacizumab and celecoxib. ( D ) Serum T levels decreased after SU5416 and celecoxib, but tumour homogenate levels were higher after all treatments. ( E ) Both serum and intratumoral DHT levels decreased after SU5416 and bevacizumab. ( F ) VEGF and SU5416 inoculation diminished circulating E1SO4 levels but augmented its intratumoral concentrations. ( G ) Serum E2 levels decreased after VEGF but augmented after SU5416, however, tumour homogenate concentrations were higher after VEGF but decreased after bevacizumab and celecoxib ( H ) Circulating and intratumoral VEGF-A levels augmented after VEGF inoculation, but these concentrations decreased only after bevacizumab. ( I ) VEGF and SU5416 treatments decreased circulating VEGF-C levels and celecoxib augmented them, however, only VEGF and SU5416 decreased intratumoral concentrations. ( J ) Only serum VEGF-D levels were augmented after VEGF and SU5416 treatments. ( K ) Serum IL-8 levels decreased after the inoculation of SU5416, bevacizumab and celecoxib, whereas its tumour levels decreased after VEGF and SU5416 but augmented after celecoxib.

Article Snippet: The SUM149 triple-negative human IBC cell line was originally obtained from Asterand, Plc. (Detroit, MI, USA) and was grown in Ham’s F-12 medium (Invitrogen, 21765029) supplemented with 5% FBS (Sigma Aldrich, 12103C), 1 ug/mL hydrocortisone (Sigma Aldrich, H4001), 5 ug/mL insulin (Sigma Aldrich, I9278) and 1% penicillin-streptomycin solution (Sigma Aldrich, P0781).

Techniques: In Vivo, Control